Literature DB >> 18275279

Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner.

Coreen M Beaumier1, Anuja Mathew, Hema S Bashyam, Alan L Rothman.   

Abstract

Dengue virus is the causative agent of dengue fever and the more-severe dengue hemorrhagic fever (DHF). Human studies suggest that the increased risk of DHF during secondary infection is due to immunopathology partially mediated by cross-reactive memory T cells from the primary infection. To model T cell responses to sequential infections, we immunized mice with different sequences of dengue virus serotypes and measured the frequency of peptide-specific T cells after infection. The acute response after heterologous secondary infections was enhanced compared with the acute or memory response after primary infection. Also, the hierarchy of epitope-specific responses was influenced by the specific sequence of infection. Adoptive-transfer experiments showed that memory T cells responded preferentially to the secondary infection. These findings demonstrate that cross-reactive T cells from a primary infection alter the immune response during a heterologous secondary infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275279     DOI: 10.1086/526790

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Authors:  Rekha Singh; Alan L Rothman; James Potts; Farshad Guirakhoo; Francis A Ennis; Sharone Green
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

4.  Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.

Authors:  Rosa Ramírez; Rosabel Falcón; Alienys Izquierdo; Angélica García; Mayling Alvarez; Ana Beatriz Pérez; Yudira Soto; Mayra Muné; Emiliana Mandarano da Silva; Oney Ortega; Ronaldo Mohana-Borges; María G Guzmán
Journal:  Virus Genes       Date:  2014-05-23       Impact factor: 2.332

5.  Interleukin-33 contributes to disease severity in Dengue virus infection in mice.

Authors:  Rafael E Marques; Anne-Gaëlle Besnard; Isabelle Maillet; Caio T Fagundes; Danielle G Souza; Bernhard Ryffel; Mauro M Teixeira; Foo Y Liew; Rodrigo Guabiraba
Journal:  Immunology       Date:  2018-09-10       Impact factor: 7.397

6.  Altered effector functions of virus-specific and virus cross-reactive CD8+ T cells in mice immunized with related flaviviruses.

Authors:  Derek W Trobaugh; Liyan Yang; Francis A Ennis; Sharone Green
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

7.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

Review 8.  Plasma leakage in dengue haemorrhagic fever.

Authors:  Anon Srikiatkhachorn
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

9.  Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.

Authors:  Daniela Weiskopf; Michael A Angelo; John Sidney; Bjoern Peters; Sujan Shresta; Alessandro Sette
Journal:  J Virol       Date:  2014-07-23       Impact factor: 5.103

Review 10.  Mouse models of dengue virus infection and disease.

Authors:  Lauren E Yauch; Sujan Shresta
Journal:  Antiviral Res       Date:  2008-07-09       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.